Zobrazeno 1 - 10
of 152
pro vyhledávání: '"Agnieszka Wozniak"'
Autor:
Annelies Verbiest, Vincent Van Hoef, Cristina Rodriguez-Antona, Jesús García-Donas, Osvaldo Graña-Castro, Maarten Albersen, Marcella Baldewijns, Annouschka Laenen, Eduard Roussel, Patrick Schöffski, Agnieszka Wozniak, Stefano Caruso, Gabrielle Couchy, Jessica Zucman-Rossi, Benoit Beuselinck
Publikováno v:
PLoS ONE, Vol 15, Iss 9, p e0238809 (2020)
Clear-cell renal cell carcinomas (ccRCC) can be divided into four transcriptomic subtypes, two of which have a favorable and two an unfavorable prognosis. To assess mechanisms driving these subtypes, we investigated their miRNA expression patterns. m
Externí odkaz:
https://doaj.org/article/30baa197e6f241efb27d73daebcccfed
Autor:
Marcin Waligora, Malgorzata M Bala, Magdalena Koperny, Mateusz T Wasylewski, Karolina Strzebonska, Rafał R Jaeschke, Agnieszka Wozniak, Jan Piasecki, Agnieszka Sliwka, Jerzy W Mitus, Maciej Polak, Dominika Nowis, Dean Fergusson, Jonathan Kimmelman
Publikováno v:
PLoS Medicine, Vol 15, Iss 2, p e1002505 (2018)
BACKGROUND:Pediatric Phase I cancer trials are critical for establishing the safety and dosing of anti-cancer treatments in children. Their implementation, however, must contend with the rarity of many pediatric cancers and limits on allowable risk i
Externí odkaz:
https://doaj.org/article/78717fdf37444366a52d4ee30a8f21ea
Publikováno v:
Studia Medyczne, Vol 40, Iss 2, Pp 208-215 (2024)
Urinary tract infections are one of the most common infections affecting outpatients and hospital patients. They are believed to affect 150 million people annually and can present as an asymptomatic infection or infections of varying course and locat
Externí odkaz:
https://doaj.org/article/dec9eda712cc4d6e934f375bd3c0c4f7
Autor:
Bruce A. Littlefield, Elodie Modave, Amy Weaver, Bram Boeckx, Diether Lambrechts, Agnieszka Wozniak, Patrick Schöffski
Publikováno v:
Clinical Cancer Research. 27:3106-3115
Purpose:A randomized phase III study evaluated the efficacy of eribulin versus dacarbazine in patients with advanced liposarcoma and leiomyosarcoma. Improved overall survival (OS) led to approval of eribulin for liposarcoma, but not for leiomyosarcom
Autor:
Judith V.M.G. Bovée, Thomas Van Cann, Iris Timmermans, Raf Sciot, Patrick Schöffski, Che-Jui Lee, Inti Zlobec, Ulla Vanleeuw, Inge H. Briaire-de Bruijn, Christian Britschgi, Jasmien Wellens, Agnieszka Wozniak
Publikováno v:
Sarcoma, Vol 2021 (2021)
Sarcoma
Sarcoma
Soft tissue sarcoma (STS) is a heterogeneous family of rare mesenchymal tumors, characterized by histopathological and molecular diversity. Tissue microarray (TMA) is a tool that allows performing research in orphan diseases in a more efficient and c
Autor:
Maarten Albersen, Benoit Beuselinck, Annelies Verbiest, Lorenzo Tosco, Annouschka Laenen, Steven Joniau, Eduard Roussel, Paul Clement, Agnieszka Wozniak
Publikováno v:
Kidney Cancer. 4:177-183
Background: Complete metastasectomy is routinely performed in selected patients with metastatic clear-cell renal cell carcinoma (ccRCC). Objectives: To assess (1) outcomes after first and repeat metastasectomy, (2) outcomes on targeted therapy in pat
Autor:
Patrick Schöffski, Hans Gelderblom, Elodie Modave, Jean-Yves Blay, Judith V.M.G. Bovée, Che-Jui Lee, Diether Lambrechts, Jozef Sufliarsky, Agnieszka Wozniak, Tom van Wezel, Raf Sciot, Maria Debiec-Rychter, Bram Boeckx
Publikováno v:
Clinical Cancer Research, 27(24), 6737-6748. AMER ASSOC CANCER RESEARCH
Purpose: The European Organization for Research and Treatment of Cancer (EORTC) clinical phase II trial 90101 “CREATE” showed high antitumor activity of crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK)/ROS1, in patients with advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::883fc9b638545a34589047cb951cd737
https://lirias.kuleuven.be/handle/123456789/681918
https://lirias.kuleuven.be/handle/123456789/681918
Autor:
Diether Lambrechts, Maria Debiec-Rychter, Bram Boeckx, Jean-Yves Blay, Patrick Schöffski, Agnieszka Wozniak, Elodie Modave, Silvia Stacchiotti, Piotr Rutkowski, Che-Jui Lee, Raf Sciot
Publikováno v:
Cancers, Vol 13, Iss 6057, p 6057 (2021)
Cancers
Cancers; Volume 13; Issue 23; Pages: 6057
Cancers
Cancers; Volume 13; Issue 23; Pages: 6057
Simple Summary Clear cell sarcoma (CCSA) is a rare subtype of soft tissue sarcoma characterized by EWSR1 rearrangement and subsequent MET upregulation. The European Organisation for Research and Treatment of Cancer 90101 phase II trial evaluated the
Autor:
Bernd Kasper, Palma Dileo, Zsuzsanna Papai, Axelle Nzokirantevye, Antoine Italiano, Charlotte Benson, Katerina Kopeckova, Saskia Litière, Isabelle Vanden Bempt, Facundo Zaffaroni, Eva Wardelmann, A. Lecesne, Olivier Mir, Nasim Ali, Agnieszka Wozniak, Patrick Schöffski, Franka Menge, Sandrine Marreaud, Sophie Cousin, Jean-Yves Blay, Hans Gelderblom
Publikováno v:
European Journal of Cancer, 134, 62-74. ELSEVIER SCI LTD
Background Gastrointestinal stromal tumour (GIST) is commonly treated with tyrosine kinase inhibitors (TKIs), but most patients ultimately develop secondary resistance. Cabozantinib, a multi-targeted TKI inhibitor, has activity in patient-derived GIS
Autor:
Jasmien Wellens, Keith R. Mehalek, Harbir S. Dhillon, Agnieszka Wozniak, Sneha S. Patil, Aya Agha, Kathleen R. Makielski, Yemarshet K. Gebreyohannes, Areej A. Ali, Anette Duensing, Jessica L. Rausch, Maria Debiec-Rychter, Yanis Tolstov, Patrick Schöffski, Donna M. Lee
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
Scientific Reports
Scientific Reports
The majority of gastrointestinal stromal tumors (GISTs) are driven by oncogenic KIT signaling and can therefore be effectively treated with the tyrosine kinase inhibitor (TKI) imatinib mesylate. However, most GISTs develop imatinib resistance through